Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
ORIC-114
i
Other names:
ORIC-114, VRN07
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(4)
News
Trials
Company:
ORIC Pharma, Voronoi
Drug class:
HER2 exon 20 mutation inhibitor
Related drugs:
‹
BI 1810631 (10)
TY-4028 (2)
BAY 2927088 (1)
DS-2087b (0)
FWD1509 (0)
HS-10376 (0)
YH42946 (0)
BI 1810631 (10)
TY-4028 (2)
BAY 2927088 (1)
DS-2087b (0)
FWD1509 (0)
HS-10376 (0)
YH42946 (0)
›
Associations
(4)
News
Trials
VERI cancer hierarchy
Reset Filters
EGFR mutation
Solid Tumor
EGFR mutation
Solid Tumor
ORIC-114
Sensitive: C2 – Inclusion Criteria
ORIC-114
Sensitive
:
C2
ORIC-114
Sensitive: C2 – Inclusion Criteria
ORIC-114
Sensitive
:
C2
EGFR exon 20 insertion
Non Small Cell Lung Cancer
EGFR exon 20 insertion
Non Small Cell Lung Cancer
ORIC-114
Sensitive: C2 – Inclusion Criteria
ORIC-114
Sensitive
:
C2
ORIC-114
Sensitive: C2 – Inclusion Criteria
ORIC-114
Sensitive
:
C2
HER-2 mutation
Solid Tumor
HER-2 mutation
Solid Tumor
ORIC-114
Sensitive: C3 – Early Trials
ORIC-114
Sensitive
:
C3
ORIC-114
Sensitive: C3 – Early Trials
ORIC-114
Sensitive
:
C3
EGFR H773_V774insH
Non Small Cell Lung Cancer
EGFR H773_V774insH
Non Small Cell Lung Cancer
ORIC-114
Sensitive: D – Preclinical
ORIC-114
Sensitive
:
D
ORIC-114
Sensitive: D – Preclinical
ORIC-114
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login